The hemostasis system is subjected to exacting regulation to meet on one hand the demands of homeostasis while on the other to avert decompensation towards thrombosis which, in context of arterial disease, is the leading cause of morbidity and mortality in western cultures. The proposed research is aimed broadly at mechanisms that limit the activity of the hemostasis system to sites of injury, with a view of the long term goal of enabling strategies for detection, suppression and ultimately prevention of thrombosis. The focus of the proposal is on mechanisms of regulation by and of the proteases that comprise the hemostasis system, particularly the control of protease specificity by regulatory subunits, by substrate structure and by inhibitors. The focal protease is thrombin, which has a plastic specificity determined by a variety of plasma and cellular effectors including heparin and other polyanions, acidic peptides, a regulatory subunit (thrombomodulin) and inhibitors. A major aim of the proposal elucidation of tertiary structural details on thrombin that are involved in interactions with effectors. The major experimental approaches is measurement of the influence of effector binding on the rate constants of reductive methylation of every lysyl residue in thrombin. In parallel, the capacity of each effector to compete with each other will be evaluated. The goal is a tertiary/quaternary structure for each thrombin-effector dimer. A related but experimentally distinct aim is the nature of the platelet membrane protein that interacts with thrombin to initiate platelet activation. The working hypothesis is that hydrolysis of a membrane protein is the initiating event. The protein will be characterized by the relative susceptibility of platelet activation to thrombins or thrombin derivatives having a broad and non-parallel distribution of specific activities toward known thrombin substrates. The thrombins will be purified from plasmas of mammals, birds, reptiles and fish, and a limited group of chemical and genetic mutants will be used. The goal is characterization of the protein sufficiently to enable its physical identification and isolation. Many of the technical developments will be capitalized on to develop a thorough, conventional enzymology of the cognate protease, factor IXa, which is likewise regulated but is poorly characterized as an enzyme. The goal is an understanding of factor IXa at a level comparable to that of thrombin. Included in the goal is the regulation of factor IXa and its substrate/product factor X/Xa by the microvascular endothelium. The latter goal will be addressed in perfused rat hearts.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL047469-02
Application #
3366674
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1992-02-01
Project End
1997-01-31
Budget Start
1993-02-01
Budget End
1994-01-31
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Smith, R D; Owen, W G (1999) Platelet responses to compound interactions with thrombin. Biochemistry 38:8936-47
Wysokinski, W E; McBane 2nd, R D; Owen, W G (1999) Individual propensity for arterial thrombosis. Arterioscler Thromb Vasc Biol 19:883-6
Machovich, R; Komorowicz, E; Kolev, K et al. (1999) Facilitation of plasminogen activation by denatured prothrombin. Thromb Res 94:389-94
Machovich, R; Owen, W G (1997) Denatured proteins as cofactors for plasminogen activation. Arch Biochem Biophys 344:343-9
Li, D; Sreenivasan, U; Juranic, N et al. (1997) Simulated dipeptide recognition by vancomycin. J Mol Recognit 10:73-87
Silvestro, L; Gupta, K; Weiser, J N et al. (1997) The concentration-dependent membrane activity of cecropin A. Biochemistry 36:11452-60
Machovich, R; Ajtai, K; Kolev, K et al. (1997) Myosin as cofactor and substrate in fibrinolysis. FEBS Lett 407:93-6
Fay, W P; Murphy, J G; Owen, W G (1996) High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi. Arterioscler Thromb Vasc Biol 16:1277-84
O'Marcaigh, A S; Nichols, W L; Hassinger, N L et al. (1996) Genetic analysis and functional characterization of prothrombins Corpus Christi (Arg382-Cys), Dhahran (Arg271-His), and hypoprothrombinemia. Blood 88:2611-8
Bichler, J; Heit, J A; Owen, W G (1996) Detection of thrombin in human blood by ex-vivo hirudin. Thromb Res 84:289-94

Showing the most recent 10 out of 22 publications